Responses

PDF
Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Prognosis of Primary Biliary Cirrhosis in Japanese Systemic Sclerosis Patients
    • Norihito Yazawa, medical doctor
    • Other Contributors:
      • Manabu Fujimoto, Masatoshi Jinnin, Zenshiro Tamaki, Ryuichi Ashida, Yoshihiro Mimura, Yoshihide Asano, Masahide Kubo, and Kunihiko Tamaki

    Dear Editor,

    We would like to add our observations to those of Rigamonti et al. regarding the prognosis of 43 primary biliary cirrhosis (PBC) in systemic sclerosis (SSc) patients (observation period: average 3.1 years)(Gut 2005;55:388). Previously, we reported that PBC-SSc patients have additional antibodies to E1-alpha epitope besides the commonly observed E2 epitope in primary PBC, revealing mild liver dysf...

    Show More
    Conflict of Interest:
    None declared.